2011 PhRMA Annual Meeting

Marc Boutin is the executive vice president and chief operating officer of the National Health Council, the only organization of its kind that brings together all segments of the health care community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers. Made up of more than 100 national health-related organizations and businesses, its core membership includes 50 of the nation’s leading patient advocacy groups. Other members include professional and membership associations, nonprofit organizations with an interest in health, and major pharmaceutical, medical device, and biotechnology companies.

Mr. Boutin has been actively involved in health advocacy, policy, and legislation throughout his career. He has designed and directed numerous strategies on issues ranging from access to health care to cancer prevention.

Mr. Boutin has a long history of board and committee service. Currently he serves as:

• Treasurer, Advisory Board to the Council for American Medical Innovation
• Member, eHealth Initiative Leadership Council
• Panel expert for the National Institutes of Health funded grant on Protecting Privacy in Health Research
• Member, Advisory Board to the Coalition Against Major Diseases
• Member, Advisory Board to the Partnership to Fight Chronic Disease
• Member, Humana Cares Clinical Advisory Board
• Member, AHRQ Effective Healthcare Program Stakeholder Group

Mr. Boutin served as a reviewer for the Institute of Medicine’s (IOM) Roundtable on Value and Science-driven Health Care. In the past he has served on the IOM’s Committee on Health Research and Privacy.

Before joining the Council, Mr. Boutin served as the vice president of government relations and advocacy at the American Cancer Society for New England and was a faculty member at Tufts University Medical School. In addition to holding senior government relations positions at Easter Seals and the Massachusetts Association of Health Boards, he was a civil rights litigator.

Mr. Boutin received his bachelor of economics degree in international politics/law from the University College of Wales, Aberystwyth, United Kingdom in 1989, and his JD from Suffolk University Law School in Boston, Massachusetts, in 1994.

For more than 25 years, James P. Firman, Ed.D. has been a leading force for innovation in services and programs for older persons. Under his leadership, NCOA has developed many nationally acclaimed programs to improve the health, independence, and continuing contributions of older adults. He has also directed NCOA’s development of world-class core competencies in expert systems, diffusion of innovation, public-private partnerships, and advocacy. Dr. Firman has served in several national leadership roles, including Chair of the Leadership Council of Aging Organizations (twice), Chair of the Access to Benefits Coalition, and Board Member of Generations of United and the National Human Services Assembly.

Prior to joining NCOA as president and CEO in January 1995, Dr. Firman was, for 10 years, founder and CEO of the United Seniors Health Cooperative (USHC), a nonprofit consumer organization. At USHC, he directed the development of the nation’s first line-of-credit reverse mortgages, the Cooperative Caring Network, a major community-wide volunteer service-credit program that helps frail and disabled persons remain at home. He also helped develop the early versions of BenefitsCheckUp, now one of NCOA’s core bodies of work.

From 1981 to 1984, Dr. Firman served as a senior program officer at The Robert Wood Johnson Foundation, where he helped develop initiatives in aging and healthcare finance, as well as the model Interfaith Volunteer Caregivers program. He is a co-founder of Grantmakers in Aging.

Dr. Firman earned his M.B.A. and his Ed.D from Columbia University.

Gail Hunt is President and CEO of the National Alliance for Caregiving, a non-profit coalition dedicated to conducting research and developing national programs for family caregivers and the professionals who serve them. Prior to heading NAC, Ms. Hunt was President of her own aging services consulting firm for 14 years. She conducted corporate eldercare research for the National Institute on Aging and the Social Security Administration, developed training for caregivers with AARP and the American Occupational Therapy Association, and designed a corporate eldercare program for EAPs with the Employee Assistance Professional Association. Prior to having her own firm, she was Senior Manager in charge of human services for the Washington, DC, office of KPMG Peat Marwick. Ms. Hunt attended Vassar College and graduated from Columbia University in New York. In May of 2004, she was appointed by the White House to serve on the Policy Committee for the 2005 White House Conference on Aging. Ms. Hunt is on the Advisory Panel on Medicare Education. She is the incoming chair for the National Center on Senior Transportation. Ms. Hunt is also on the Board of Commissioners for the Center for Aging Service Technology and she is also on the steering committee for Long-Term Care Quality Assurance. Additionally, Ms. Hunt is on the Governing Board of the Patient-Centered Outcomes Research Institute (PCORI).

Nancy Brown is Chief Executive Officer of the American Heart Association, the world’s largest voluntary health organization dedicated to preventing, treating and defeating cardiovascular diseases and stroke. The association is a global leader in the discovery and dissemination of heart and stroke research and is highly respected for its professional and public education programs, legislative leadership through advocacy and long history of responsible fiscal management.

Since becoming CEO on January1, 2009, Nancy has led the organization to a number of significant advances, including:

• Development of the AHA’s bold new 2020 Impact Goal: To improve the cardiovascular health of all Americans by 20 percent while reducing deaths from cardiovascular diseases and stroke by 20 percent.
• A new focus on prevention through the AHA’s 2010-13 strategic plan.
• Achievement of AHA’s longtime advocacy priority of healthcare reform that is focused on providing high quality, affordable and accessible healthcare to patients. 
• Launching the development of new revenue strategies and business initiatives to support AHA’s mission. 
• Creating the Vision for Volunteerism initiative designed to create even more significant opportunities for volunteers to impact the mission of AHA. 
• Creating a culture of innovation, initiating the CEO Innovation Think Tank of staff and volunteer leaders. 
• Development of the Association’s Global Strategic Plan.

Prior to being named CEO, Nancy was the AHA’s Chief Operating Officer for the eight prior years. In this role she managed the Association’s mission, science and business functions and led the AHA’s integrated strategy to achieve its 2010 Impact Goal to reduce coronary heart disease, stroke and risk by 25 percent.

Nancy currently serves on the boards of the Campaign for Tobacco Free Kids, the National Health Council and the Partnership for Prevention.

Before joining the AHA, Nancy served as the Director of Development/Deputy Director of the Endowment Campaign for the Michigan Cancer Foundation, and as Special Events Director for Mount Carmel Mercy Hospital in Detroit.

Martin J. Murphy, Jr., PhD (New York University), DMedSc (Queen’s University- Belfast, h.c.) is Founding Chairman and Chief Executive Officer of AlphaMed Consulting, Inc., that provides strategic support for academic cancer centers and cancer drug development programs of global pharmaceutical and biotechnology companies. Founding Executive Editor of the 15-year-old peer-reviewed journal, The Oncologist, he is also the Founding Executive Editor of Stem Cells, a 28-year-old journal of stem cell biology and regenerative medicine. Dr. Murphy was founder and former Chief Executive Officer of the Hipple Cancer Research Center, NIH principal investigator and author of more than 150 peer-reviewed papers. In addition to director of Jennerex Biotherapeutics he is a director of Aldagen, Inc., a clinical-stage regenerative medicine company developing and commercializing stem cell derived clinical products. Dr. Murphy was a charter member of the Scientific Advisory Board of Pappas Ventures, Inc. (2002-2008) and is a member of the Scientific Advisory Board (Dr. Herbert Boyer, chair) of Hatteras Venture Partners. He is a member of Queen’s University-Belfast School of Medicine International Review Board, chairman of The ASCO Cancer Foundation, a founding director of the All-Ireland Cancer Foundation, and a former director of the American Cancer Society Foundation (2000-2009). A director of the Foundation for the National Institutes of Health (Dr. Charles Sanders, chair), Dr. Murphy is a member of the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center, member of the Board of Advisors of the H. Lee Moffitt Cancer Center & Research Institute (Sam Donaldson, chair) and a charter member and director of C-Change co-chaired by former President George H. W. Bush and former First Lady Barbara Bush; U.S. Senator Dianne Feinstein, vice chair. Dr. Murphy is Chief Executive Officer of the non-profit CEO Roundtable on Cancer at the request of former President Bush. William C. Weldon is chairman, Christopher A. Viehbacher, chairman-elect, and Robert A. Ingram was founding chairman of the CEO Roundtable on Cancer. Dr. Murphy has been married for 45 years to Dr. Ann Murphy, president of AlphaMed Press. They have five children and ten grandchildren. He is a citizen of the United States and Ireland.

Garry has broad experience in the science, medicine and pharmaceutical development. He has held a number of senior positions within J&J, most recently Group President, Johnson and Johnson Pharmaceutical Research and Development where he was responsible for maximizing existing strengths and leveraging collective resources to bring innovative new molecular entities (NMEs) to market quickly and cost effectively. Through a number of new initiatives he helped transform J&J’s pharmaceutical R&D to a much more capable and productive organization and helped recruit a number of top scientists. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases, gained initial or new and/or expanded indication approvals.

Garry joined J&J in 2002 as Senior Vice President of Drug Development at Johnson & Johnson Pharmaceutical Research and Development (J&JPRD). In 2005, Garry became President of J&JPRD, and in 2006, was promoted to Group President. Before joining J&JPRD, he held senior-level positions with Astra Merck Inc., Astra Pharmaceuticals, Astra Zeneca and Merck KGaA. He has also held a number of academic posts at a number of academic institutes including the Ludwig Institute for Cancer Research, the University of Toronto, the University of Iowa College of Medicine and the University of Pennsylvania (adjunct).

Garry has written more than 50 articles and book chapters. He holds a Bachelor of Science degree from the University of Saskatchewan and a medical degree from the University of Saskatchewan College of Medicine and completed his postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. He also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He is a Fellow of the American College of Physicians, a Fellow of the American College of Gastroenterology, a member of the American Association of Immunologists, and the Society for Clinical Trials. He is a member of the Board of the Reagan Udall Foundation, the J&J Development Corporation and is J&J’s representative to, and Vice Chairman, of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Committee, Vice Chairman and Treasurer of the PhRMA Foundation Board, a member of the Board of Trustees for the Robert Wood Johnson Medical School, a member of the Scientific Advisory Board of the Center for Advanced Biotechnology and Medicine (Rutgers), a member of the Executive Committee of the Biomarkers Consortium, and a member of the Board of Trustees of the Newark Boys Chorus School. He is also the 2007 discovery awardee of the American Geriatrics Society.

Dr. Martin Mackay is the President of Research & Development at AstraZeneca Pharmaceuticals. He leads a global organisation tasked with advancing a portfolio on investigational medicines across a range of disease areas. Martin is a member of the AstraZeneca Senior Executive Team, Portfolio Investment Board and the Science Committee. Prior to joining AstraZeneca in 2010, Martin was the President of PharmaTherapeutics Research & Development at Pfizer. His career at Pfizer spanned 15 years, where he held various leadership roles, including the President of Research & Development.

Born in Scotland, Martin earned a first class honours degree in Microbiology at Heriot-Watt University and a PhD in Molecular Genetics at the University of Edinburgh. Between degrees he worked in Antibacterial Discovery at Beecham Pharmaceuticals in Surrey, UK. Martin conducted his postdoctoral research fellowship working on malarial vaccines with Professor John Scaife at the University of Edinburgh and Professor Uli Certa at Hoffman La-Roche Pharmaceuticals in Basel, Switzerland. Martin joined the Advanced Drug Delivery Research Unit at Ciba-Geigy in the UK and became the Head of Drug Preformulation and Delivery. In 1993, he moved to Ciba’s headquarters in Basel, Switzerland as Head of Molecular and Cell Biology, CNS Research, where he led an international team of researchers until his move to Pfizer in 1995.

He serves on the Scientific and Regulatory Committee of the industry trade group PhRMA and co-chairs the US-India BioPharma & Healthcare Summit Advisory Board. Martin is a Visiting Professor at the University of Lincoln, UK.

Pops has been Chief Executive Officer of Alkermes since February 1991. A native of Los Angeles, California, Richard received a B.A., in Economics from Stanford University in 1983. From 1984 to 1991, he was employed by PaineWebber, Inc., in New York as Vice President of PaineWebber Development Corporation, providing product development financing for the country's leading biotechnology and high-technology companies.

Accomplishments
Under Richard's leadership, Alkermes has grown from a privately held company with 25 employees to a publicly traded, leading specialty pharmaceutical company (NASDAQ:ALKS) with more than 400 employees in multiple locations in the United States. The company has raised over $600 million to support the research and development of its product candidates and has consummated important strategic alliances with major pharmaceutical companies, including: Serono, S.A., Eli Lilly and Company, Genentech, Inc., and Janssen Pharmaceutica, Inc.

Outside Directorships
Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; Reliant Pharmaceuticals, LLC; CombinatoRx, Inc.; Expressive Constructs, Inc.; the Biotechnology Industry Organization (BIO)(former Chairman); the Massachusetts Biotechnology Council (MBC); the New England Healthcare Institute (NEHI); Harvard Medical School Board of Fellows and The Fessenden School Board of Trustees. He also serves as Chair for the Harvard Medical School Advisory Council for Biological Chemistry & Molecular Pharmacology (BCMP) and is an Advisory Board Member of Polaris Venture Partners.

Dr. Leshner has been Chief Executive Officer of the American Association for the Advancement of Science and Executive Publisher of the journal Science since December 2001. AAAS (triple A-S) was founded in 1848 and is the world's largest, multi-disciplinary scientific and engineering society.

Before coming to AAAS, Dr. Leshner was Director of the National Institute on Drug Abuse (NIDA) from 1994-2001. One of the scientific institutes of the U.S. National Institutes of Health, NIDA supports over 85% of the world's research on the health aspects of drug abuse and addiction.

Before becoming Director of NIDA, Dr. Leshner had been the Deputy Director and Acting Director of the National Institute of Mental Health. He went to NIMH from the National Science Foundation (NSF), where he held a variety of senior positions, focusing on basic research in the biological, behavioral and social sciences, science policy and science education.

Dr. Leshner went to NSF after 10 years at Bucknell University, where he was Professor of Psychology. He has also held long-term appointments at the Postgraduate Medical School in Budapest, Hungary; at the Wisconsin Regional Primate Research Center; and as a Fulbright Scholar at the Weizmann Institute of Science in Israel. Dr. Leshner is the author of a major textbook on the relationship between hormones and behavior, and has published over 150 papers for both the scientific and lay communities on the biology of behavior, science and technology policy, science education, and public engagement with science.

Dr. Leshner received an undergraduate degree in psychology from Franklin and Marshall College, and M.S. and Ph.D. degrees in physiological psychology from Rutgers University. He also has been awarded six honorary Doctor of Science degrees. Dr. Leshner is an elected fellow of AAAS, the National Academy of Public Administration, the American Academy of Arts and Sciences, and many other professional societies. He is a member of the Institute of Medicine of the National Academies of Science and Vice-Chair of its governing Council. The U.S. President appointed Dr. Leshner to the National Science Board in 2004. He is also a member of the Advisory Committee to the Director of NIH.

Bob Ingram is General Partner in the firm Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies in the southeast United States.

Bob began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. Upon reaching the mandatory retirement age of 60, he was asked by the Board to serve as Vice Chairman Pharmaceuticals, GSK, which he did until January 1, 2010, at which time he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline plc.

He has served as Chairman, Valeant Pharmaceuticals International, since December 12, 2010. On January 26, 2011 he was appointed Chairman of Elan Corporation, plc. He also serves on the Board of Directors of Allergan Inc., Cree, Inc., Edwards Lifesciences Corporation, and Lowe's Companies, Inc.

In addition to his professional responsibilities, Bob was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on Cancer on whose Board he currently serves. He is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.

Bob is a member of the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, Project HOPE, Research Triangle Foundation of North Carolina, Research Triangle Institute International, and H. Lee Moffitt Cancer Center. He also serves as Chairman of the N.C. GlaxoSmithKline Foundation. Bob graduated from Eastern Illinois University with a BS degree in Business Administration.

As head coach of the Duke Blue Devils for over 30 years, Basketball Hall of Famer and current national championship coach Mike Krzyzewski has made a career of motivating people both on and off the court. Affectionately known as “Coach K,” Krzyzewski coached the 2008 U.S. men’s national team to its first gold medal since the 2000 Summer Olympics in Sydney, Australia. Known as the “Redeem Team” for its success both on and off the court, the team had a perfect 8–0 record during the Olympics and solidified U.S. basketball’s return to dominance under Coach K’s leadership. He will direct Team USA in the 2010 world championships in Turkey and the 2012 Olympics in London.

During his tenure at Duke, Coach K has led his team to 4 NCAA Championships, 11 Final Fours and 12 Atlantic Coast Conference Championships. Currently the all-time winningest active coach in men’s Division I basketball, Coach K has amassed an NCAA- record 77 tournament victories while averaging more than 25 wins per season. During the 2009-2010 season, Coach K led his team to win the NCAA Tournament as well as the ACC Tournament Championship.

Prior to coaching at Duke, Coach K spent five years building the men’s basketball program at his alma mater, West Point. Overall, Coach K has an 814–168 career record and a 741–209 record at Duke. On November 17, 2000, he earned his 500th win at Duke with a triumph over Villanova. That night, the fabled floor of Duke’s Cameron Indoor Stadium was dedicated as Coach K Court.

These accomplishments have not gone unnoticed. In all, Coach K has been named National Coach of the Year 12 times in 8 different seasons. He was named Coach of the Decade for the 1990s by the NABC and was the second recipient of the John R. Wooden Legends of Coaching Award. In 2001, Coach K was one of three members inducted into the Naismith Memorial Basketball Hall of Fame, with the presentation made by his college coach Bob Knight.

Krzyzewski received another prestigious honor in 2001, being named “America’s Best Coach”—all coaches, any sport, any level of play—by Time magazine and CNN. “No college hoops coach has won more in the past two decades,” wrote Josh Tyrangiel of Time “and Krzyzewski has accomplished all this with a program that turns out real-deal scholar athletes—kids who go to class, graduate and don’t mind telling everyone about it.”

Krzyzewski’s book, Beyond Basketball: Coach K’s Keywords for Success, was published in 2006. His most recent book, The Gold Standard: Building a World-Class Team, was co-authored with his youngest daughter, Jamie Spatola, and was released in 2009. In 2009, Sporting News named Krzyzewski one of the 50 greatest coaches of all time.

John Castellani became President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America in August 2010.

As PhRMA’s President and CEO, Mr. Castellani leads an organization that represents America’s leading pharmaceutical research and biotechnology companies, which directly employ more than 600,000 men and women nationwide working to create new medicines that help patients the world over fight disease and live longer, healthier lives. PhRMA members are among the most innovative research-based companies in the world, investing an estimated $45.8 billion in new medical research and development in 2009 alone.

In assuming his new responsibilities, Mr. Castellani has pledged that PhRMA will continue to lead efforts to find patient-centered solutions to healthcare challenges in America and around the globe. In particular, PhRMA will focus on helping to successfully implement -- and improve -- the recently enacted healthcare reform law and will work to build a dynamic environment in the United States that promotes and rewards medical innovation.

Before joining PhRMA, Mr. Castellani was President and Chief Executive Officer of Business Roundtable, an association of chief executive officers of leading U.S. corporations with a combined workforce of nearly 12 million employees and $6 trillion in annual revenues. Business Roundtable was cited by The Financial Times as "the most influential chief executive lobbying group in the U.S." and is at the forefront of public policy debates, advocating for a vigorous, dynamic global economy. Mr. Castellani served at the Business Roundtable from May 2001 to July 2010, where he significantly strengthened the Roundtable’s reputation in Washington, nationally and internationally.

Under Mr. Castellani, the Roundtable played vital roles in the adoption of long-awaited civil-justice reform legislation in 2005, approval of the Central America Free Trade Agreement, and enactment of critically important legislation to lower tax rates and slash taxes on dividends in 2003. He also was a leader of the coalition working in support of Social Security reform, the “Divided We Fail” partnership formed to urge congressional action on healthcare reform and retirement security, and other initiatives to keep the United States competitive and a global hub of innovation.

Mr. Castellani is frequently sought by the news media for his expert insights on business and public policy issues, appearing on such programs as NBC’s “Meet the Press,” PBS’ “The NewsHour with Jim Lehrer,” Fox News Channel’s “Special Report,” and CNBC’s “Street Signs.” He also regularly testified before Congress on issues of key concern to the Business Roundtable, and discussed the Roundtable’s agenda for economic growth in venues such as the Detroit Economic Club and the National Conference of State Legislatures.

Before becoming President of the Business Roundtable, Mr. Castellani was Executive Vice President of Tenneco Inc. and part of the senior management team that led the transformation of the ailing conglomerate into seven strong companies.

Mr. Castellani’s Washington experience includes serving as Vice President for Resources and Technology with the National Association of Manufacturers, and as Vice President of State, Federal and International Government Relations for TRW Inc. He started his career at General Electric as an environmental scientist and strategic planner.

In 2007, Castellani was named one of the 100 most influential people in corporate governance by Directorship Magazine.

A graduate of Union College in Schenectady, N.Y., Mr. Castellani now serves on its board of trustees. He is also an Ethics Resource Center Executive fellow and a member of the Advisory Council of the Business Roundtable Institute for Corporate Ethics, in addition to being a member of The Economic Club of Washington. He and his wife, Terry, reside in Washington and have two sons.

Fred Hassan Chairman of the Board Bausch + Lomb Fred Hassan is a Partner with the private equity firm, Warburg Pincus. He is also Chairman of Bausch & Lomb, as well as Board member of Time Warner and Avon where he serves as Lead Director.

Fred Hassan is the former Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003, Hassan was Chairman and Chief Executive Officer of Pharmacia Corporation – a company that was formed in March 2000 as a result of the merger of Monsanto and Pharmacia and Upjohn. Hassan joined Pharmacia & Upjohn as Chief Executive Officer in 1997.

Previously, Hassan was Executive Vice President of Wyeth, formerly known as American Home Products, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth’s Board of Directors in 1995. Earlier in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business.

Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School. Hassan has chaired three significant pharmaceutical industry organizations - The Pharmaceutical Research and Manufacturers of America (PhRMA), The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) and the HealthCare Institute of New Jersey (HINJ). Mr. Hassan is a member of The Business Council and the American Institute for Stuttering.

Bob Ingram is General Partner in the firm Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies in the southeast United States.

Bob began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. Upon reaching the mandatory retirement age of 60, he was asked by the Board to serve as Vice Chairman Pharmaceuticals, GSK, which he did until January 1, 2010, at which time he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline plc.

He has served as Chairman, Valeant Pharmaceuticals International, since December 12, 2010. On January 26, 2011 he was appointed Chairman of Elan Corporation, plc. He also serves on the Board of Directors of Allergan Inc., Cree, Inc., Edwards Lifesciences Corporation, and Lowe's Companies, Inc.

In addition to his professional responsibilities, Bob was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on Cancer on whose Board he currently serves. He is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.

Bob is a member of the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, Project HOPE, Research Triangle Foundation of North Carolina, Research Triangle Institute International, and H. Lee Moffitt Cancer Center. He also serves as Chairman of the N.C. GlaxoSmithKline Foundation. Bob graduated from Eastern Illinois University with a BS degree in Business Administration.

Sidney Taurel is senior advisor of Capital Royalty and chairman emeritus of Eli Lilly and Company.

Born a Spanish citizen in Casablanca, Morocco, Taurel became an American citizen in November 1995. After graduating from École des Hautes Études Commerciales, in Paris, France, in 1969, he received a master of business administration degree from Columbia University in 1971.

Taurel joined Eli Lilly and Company in 1971 as an international marketing associate. His 37-year career included 15 years in Brazil, France, Eastern Europe, and the UK. He became president of Lilly International in 1986, president of the Pharmaceutical Division in 1993, COO in 1996, CEO in 1998, and chairman of the board in 1999. He retired as chairman and CEO in 2008.

Taurel is chairman of the Strategic Advisory Committee for Capital Royalty, LLC. He is also a member of the boards of IBM Corporation, McGraw-Hill Companies, Inc., and BioCrossroads. In addition, Taurel is a member of the global advisory boards for Takeda and Almirall. He serves on the board of overseers of the Columbia Business School, is a member of the Business Council, and a trustee at the Indianapolis Museum of Art. Taurel is a past president of Pharmaceutical Research and Manufacturers of America (PhRMA) and a former member of the board of ITT Industries.

Taurel received three Presidential appointments: to the Homeland Security Advisory Council (2002-2004), the President’s Export Council (2002-2007), and the Advisory Committee for Trade Policy and Negotiations (2007-2009). He is an officer of the French Legion of Honor.

Taurel is fluent in English, French, Spanish and Portuguese. He and his wife Kathryn live in Key Biscayne and Indianapolis and have three grown children and one grandchild.

Roy Vagelos is Retired Chairman and CEO of Merck & Co., Inc. He received an AB in 1950 from the University of Pennsylvania and an MD in 1954 from Columbia University. Following a residency at the Massachusetts General Hospital, he joined the National Institute of Health where from 1956-66 he served as Senior Surgeon and then Section Head of Comparative Biochemistry. In 1966 he became Chairman, Department of Biological Chemistry, Washington University School of Medicine in St. Louis and in 1973 founded the University's Division of Biology and Biomedical Sciences. He joined Merck Research Laboratories in 1975 where he was president until 1985 when he became CEO and later Chairman of the company. He retired in 1994.

Dr. Vagelos is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. He has received many awards in science and business as well as 14 honorary doctorates. In the past he was Chairman of the Board of the University of Pennsylvania, a member of The Business Council and The Business Roundtable, and served on the boards of TRW, McDonnell Douglas, Estee Lauder and Prudential Finance. He also served as Co-chairman of the New Jersey Performing Arts Center and President and CEO of the American School of Classical Studies in Athens.

He is currently Chairman of Regeneron Pharmaceuticals, a biotech company. He is also Chairman of the Board of Visitors at Columbia University Medical Center where he also chairs the Capital Campaign. He serves on a number of public policy and advisory boards, including the Donald Danforth Plant Science Center and the National Math & Science Initiative.

Mike Huckman has covered it all. From drug approvals to drug recalls, mega-mergers to baby-biotech IPOs, from the epidemic of “diabesity” to pandemic flu scares. And now Mike brings his nearly three decades of reporting experience to MSL New York.

Prior to joining the firm, Mike spent almost 10 years at business cable network CNBC where he reported on the drug, biotech and medical device industries. He earned a reputation as a go-to journalist on breaking stories in those sectors and for scoring dozens of exclusive interviews with CEOs and key opinion leaders.

In May 2010, Mike joined MSL where he serves in a variety of roles ranging from providing senior level media counsel to the firm's clients, contributing to new business development, as well as thought leadership in healthcare PR. In his previous career, Mike won many awards, including three Emmys, one of them for business and financial reporting.

Mike is a proud graduate of the University of Southern California.

Ellen V. Sigal, PhD
Chairperson and Founder, Friends of Cancer Research

Ellen V. Sigal, PhD, is Chairperson and Founder of Friends of Cancer Research (“Friends”), a cancer research think tank andadvocacy organization based in the Washington, DC metropolitan area. Friends is dedicated to accelerating the nation's progress toward prevention and treatment of cancer by mobilizing public support for cancer research funding and providing education on key public policy issues. For more than 14 years, Friends has pioneered innovative public‐private partnerships, organized critical policy forums, educated the public and brought together key communities to develop collaborative strategies in the field of cancer research.

Dr. Sigal is Vice Chair of the inaugural board of directors of the Reagan‐Udall Foundation, a partnership designed to modernize medical product development, accelerate innovation, and enhance product safety in collaboration with the U.S. Food and Drug Administration. She serves on the National Institutes of Health Foundation Board chairing its Public‐Private Partnerships Committee, the American Association for Cancer Research Foundation Board, and the Research! America Board. Dr. Sigal is a member of the Stand Up To Cancer (SU2C) Advocate Advisory Council, and she is one of two Council members nominated to the SU2C Scientific Advisory Committee. She holds leadership positions with a broad range of cancer advocacy and public policy organizations, and leadership positions with academic health centers including the M. D. Anderson Cancer Center External Advisory Board, the Duke University Cancer Center Board of Overseers, and The Sidney Kimmel Comprehensive Cancer Center Advisory Council. She serves on the C‐Change Research Committee and the Entertainment Industry Foundation Oversight Committee for the Biomarker Discovery Project. Dr. Sigal was recently named to the Patient Centered Outcomes Research Institute (PCORI) Board of Governors as a representative of patients and health consumers.

During her more than twenty year commitment to cancer research, Dr. Sigal has served in a number of critical public positions. She served on the National Cancer Institute Board of Scientific Advisors from 2003‐2009, and the National Institutes of Health Director’s Council of Public Representatives from 2003−2006. She was a Presidential Appointee to the National Cancer Advisory Board from 1992‐1998, where she chaired the Budget and Planning Committee that oversees the federal cancer budget. In 1998, Dr. Sigal was named Vice Chairman of the Board of The March, a national grassroots advocacy group that brought thousands of volunteers to Washington to liaise with Congress and to set a new advocacy agenda for cancer research and treatment. She is a past member of the American Society of Clinical Oncology Foundation Board. Dr. Sigal has also been instrumental in harnessing the energies of Hollywood on behalf of cancer research, serving as President of The Creative Community Task Force for Cancer Research.

Mr. Vradenburg is a prime example of the “encore career”. Nominally retired since 2003, he is a civic activist and philanthropist driven by an insatiable curiosity, a wide range of interests and a passion for public service (though not public office) and a determination to “make a difference.”

He currently serves as Chairman of the Board of USAgainstAlzheimer’s (dedicated to stopping Alzheimer’s by 2020) and the Geoffrey Beene Foundation-Alzheimer's Initiative (committed to the early diagnosis and treatment of Alzheimer's disease), as well as Chairman of The Phillips Collection (the nation’s first modern art museum). Additionally, Mr. Vradenburg currently serves as Vice Chairman of the Chesapeake Crescent Initiative (a public/private collaboration involving Maryland, Virginia, the District of Columbia and the Federal Government focused on life science, energy and security). He serves on the board of the United Way of the National Capital Area, the University of the District of Columbia Foundation, iKeepSafe (Internet Keep Safe Coalition), the Regional Association of Washington Grantmakers, and the INOVA Health System Foundation. Mr. Vradenburg is also a member of the Council on Foreign Relations and the Economic Club of Washington.

Prior to December 2003, Mr. Vradenburg was Strategic Advisor, AOL Time Warner, having served in senior executive positions at AOL, AOL Time Warner and Time Warner. In those positions, Mr. Vradenburg set the Company’s strategy to create a policy framework designed to foster the Internet’s global economic, social and civic value. Before joining America Online, Mr. Vradenburg served as Senior Vice President and General Counsel of CBS Inc. and Executive Vice President of Fox, Inc. He then launched the Entertainment & Media Practice Group of the law firm of Latham & Watkins.

Mr. Vradenburg received his B.A. from Oberlin College, magna cum laude, where he was elected to Phi Beta Kappa, and his J.D. cum laude from Harvard Law School. His wife, Trish, is a TV sitcom writer, a playwright, book author and magazine and newspaper columnist; his daughter, Alissa, is a Talent Manager in Los Angeles, and his son, Tyler, is a high school teacher, guidance counselor and football coach in Chicago. Mr. Vradenburg has four beautiful grandchildren under the age of 4-years-old. They are all on their way to Harvard.

Christine C. Ferguson, J.D. is a Professor in the School of Public Health and Health Services at The George Washington University. She is also charged with coordinating the day to day activities of the STOP Obesity Alliance. In addition to her research agenda in obesity, her other areas of focus include national health reform, Medicaid, health care financing, health care and management, child health and development, public health preparedness and state health policy.

Ms. Ferguson's prior professional experiences have made her adept at evaluating, prioritizing and working to address significant public health and health care financing issues. As Commissioner of Public health in Massachusetts, Ms. Ferguson oversaw the Department of Public Health and the Department of Health Care Finance and Policy. She led initiatives addressing public health emergencies, established a unique collaboration with the Executive Office of Public Safety, and implemented the Betsy Lehman Center for Patient Safety and Medical Errors Reduction. She was also a key member of a two-year effort to establish a new department for Early Education and Child Care.

From 1995 to 2001, Ms. Ferguson ran the Rhode Island Department of Human Services under Governor Lincoln Almond's two-term administration. She oversaw nearly one-third of the State's annual budget, providing Medicaid and services for low-income families, children, senior citizens, veterans and the disabled. Rhode Island's innovative achievements in health care, Medicaid managed care, early education and child care and welfare reforms were widely recognized during her tenure. Of particular note, Rhode Island had the nation's highest percentage of children with health care coverage.Prior to her service in Rhode Island, Ms. Ferguson also served as counsel and deputy chief of staff to the late U.S. Senator John H. Chafee and was instrumental in developing a bipartisan health reform proposal in the 1990s.

Ms. Ferguson is currently a member of the Board on Children, Youth and Families for the Institute of Medicine National Academies and a Director on the Board of Blue Cross Blue Shield of RI. She has served on the boards of the National Academy of State Health Policies and a variety of other national organizations.

Ms. Ferguson has been recognized as being one of the Most Influential Health Policymakers by Faulkner & Gray Healthcare, one of the nation's 100 most influential lawyers by the National Law Journal and one of the top 25 Most Influential Working Mothers by Working Mothers Magazine.

Ms. Ferguson holds a B.A. from the University of Michigan and a J.D. from Washington College of Law, American University.

Matthew L. Myers is President of the Campaign for Tobacco-Free Kids, a privately funded organization established to reduce tobacco use and its devastating consequences in the United States and around the world. Over the last 25 years, Mr. Myers has participated in virtually every major national tobacco-related legislative effort and has worked with state tobacco prevention advocates and officials around the country. In 1999, Mr. Myers was asked to serve on the first advisory committee established to advise the Director General of the World Health Organization on tobacco issues. The following year, Mr. Myers was named by President Clinton to co-chair a Presidential Commission to examine the economic problems being experienced by tobacco farmers and their communities and recommend possible solutions. In October 2004, the Harvard School of Public Health bestowed its highest honor, the prestigious Julius B. Richmond award, on Mr. Myers for his work as an advocate in preventing tobacco industry marketing to children. In October 2007, the American Cancer Society bestowed its highest award, the Medal of Honor for Cancer Control, on Mr. Myers for his relentless work to eliminate tobacco use.

John W. Robitscher is the chief executive officer of the National Association of Chronic Disease Directors (NACDD), whose mission is to provide state-based leadership and expertise for chronic disease prevention and control at the state and national level. Using his skills in organizational and strategic planning and fundraising, Robitscher has improved the association’s organizational efficiency, streamlined operations and expanded organizational capabilities.

Prior to joining NACDD, Robitscher was the executive director of the Henry W. Grady Foundation, serving Grady Memorial Hospital. Robitscher was also the former State of Georgia director of Rural Health, where he worked to develop regional health planning, coordination and policy to improve the overall health status of Georgians.

Robitscher earned his bachelor’s and master’s degrees in public health from Emory University. His distinguished contributions to the disadvantaged were recognized by Emory University in 1992, when he was honored with a Humanitarian Award.

Kenneth Thorpe, Ph.D., is the Robert W. Woodruff Professor and Chair of the Department of Health Policy & Management, in the Rollins School of Public Health of Emory University, Atlanta, Georgia. He is also the executive director of the Emory Institute for Advanced Policy Solutions at Emory University.

As executive director of the Partnership to Fight Chronic Disease (PFCD), Thorpe works with a coalition of over 120 national and state-based organizations consisting of patients, providers, community organizations, business and labor groups, and health policy experts to raise awareness of the negative impact chronic disease has on the nation’s health and economy.

In addition to holding a number of faculty positions, Thorpe was Deputy Assistant Secretary for Health Policy in the U.S. Department of Health and Human Services from 1993 to 1995. In this capacity, he coordinated all financial estimates and program impacts of President Clinton’s health care reform proposals for the White House. He also directed the administration’s estimation efforts in dealing with Congressional health care reform proposals during the 103rd and 104th sessions of Congress.

As the executive director of the PFCD and respected health care expert, Thorpe regularly testifies before numerous committees in the U.S. Senate and House on many aspects of health care reform, including disease prevention, wellness and coordination of care.

Thorpe has authored and co-authored over 85 articles, book chapters and books and is a frequent national presenter at health care conferences, television and the media. He has appeared on Nightline with Ted Koppel, NBC News with Tom Brokow, ABC World News Tonight with Peter Jennings, CNN, CNBC and Newshour with Jim Lehrer.

Previous academic positions held by Thorpe include the Vanselow Professor of Health Policy and Director, Institute for Health Services Research at Tulane University; Professor of Health Policy and Administration at the University of North Carolina at Chapel Hill; Associate Professor and Director of the Program on Health Care Financing and Insurance at the Harvard University School of Public Health; and Assistant Professor of Public Policy and Public Health at Columbia University. Thorpe has also held Visiting Faculty positions at Pepperdine University and Duke University.

In 1991, Thorpe was awarded the Young Investigator Award presented to the most promising health services researcher in the country under age 40 by the Association for Health Services Research. He also received the Hettleman Award for academic and scholarly research at the University of North Carolina and was provided an “Up and Comers” award by Modern Healthcare.

Thorpe received his Ph.D. from the Rand Graduate School, an M.A. from Duke University and his B.A. from the University of Michigan.

In August 2010 Fareed Zakaria joined TIME as Editor-at-Large, writing a biweekly column and contributing cover stories and features in the magazine and on TIME.com. He also is serving as a consultant for HBO's documentary unit. He continues to write a regular column for The Washington Post. In October 2000 he was named editor of Newsweek International, overseeing all of Newsweek's editions abroad until the fall of 2010. He wrote a regular column for Newsweek, which also appeared in Newsweek International and often The Washington Post. He has served as an analyst for ABC News, a roundtable member on This Week with George Stephanopoulos, and host of Foreign Exchange on PBS. In Spring 2008 he launched a new weekly foreign affairs program, Fareed Zakaria GPS, airing on CNN worldwide. On the program Zakaria conducts in-depth interviews with world leaders such as Tony Blair, Wen Jiabao, Henry Kissinger, Luiz Inácio Lula da Silva, and Barack Obama.

At age 28 Zakaria became the youngest managing editor in the history of Foreign Affairs, the widely-circulated journal of international politics and economics. Prior to joining Foreign Affairs, Zakaria ran a major research project on American foreign policy at Harvard University, where he taught international relations and political philosophy. He has written for such publications as The New York Times, The Wall Street Journal, The New Yorker, The New Republic, and Slate.

His book, The Post-American World, is about the "rise of the rest" -- the growth of China, India, Brazil and many other countries -- as the great story of our time. It was published in May 2008 and became an immediate New York Times bestseller. In a fully revised and updated edition, The Post- American World: Release 2.0 (May 2011), Zakaria reviews the shifts of power he originally identified, marvels at how quickly they have occurred, and discusses the vast political and economic implications. Zakaria's The Future of Freedom (2003) is a global analysis of how democracy has changed every aspect of our lives — from economics and technology to politics and social relations. This book also became an international bestseller and has been translated into 20 languages. He is also the author of From Wealth to Power: The Unusual Origins of America's World Role (Princeton University Press), which has been translated into several languages, and co-editor of The American Encounter: The United States and the Making of the Modern World (Basic Books).

Zakaria won two Overseas Press Club Awards with Newsweek reporting teams and has been nominated for two National Magazine Awards. He won the Deadline Club Award for Best Columnist and numerous honors for his October 2001 Newsweek cover story, “Why They Hate Us,” which the Boston Globe said, “ought to be mandatory reading in every home in America.” In 1999 he was named “one of the 21 most important people of the 21st Century” by Esquire magazine. He serves on the boards of the Trilateral Commission, the International Institute of Strategic Studies and The Council of Foreign Relations, among others.

He received a B.A. from Yale and a Ph.D. in political science from Harvard. He lives in New York City with his wife, son, and two daughters.